slc6a4 Protein

Serotonin Transporter (SERT) Protein

Pathway Diagram

```mermaid
flowchart TD
SLC6A4["SLC6A4<br/>(Serotonin Transporter)"]

%% Serotonin Transport Function
SLC6A4 -->|"transports"| Serotonin["5-HT Reuptake<br/>Regulation"]
Serotonin -->|"modulates"| Synaptic["Synaptic<br/>Transmission"]

%% Associated Genes/Proteins
SLC6A4 -->|"interacts_with"| APOE["APOE<br/>(Alzheimer Risk)"]
SLC6A4 -->|"interacts_with"| LRRK2["LRRK2<br/>(Parkinson Risk)"]
SLC6A4 -->|"metabolized_by"| CYP3A4["CYP3A4<br/>(Drug Metabolism)"]

%% Epigenetic Regulation
SLC6A4 -->|"activates"| Epigenetic["Epigenetic<br/>Modifications"]
Epigenetic -->|"regulates"| Gene_Expression["Gene Expression<br/>Changes"]

%% Neuropsychiatric Associations
SLC6A4 -->|"dysregulation"| Depression["Major Depressive<br/>Disorder"]
SLC6A4 -->|"dysregulation"| Anxiety["Anxiety<br/>Disorders"]
Depression -->|"comorbid_with"| Dementia["Dementia<br/>Risk"]

%% Neurodegenerative Diseases
SLC6A4 -->|"associated_with"| Alzheimer["Alzheimer's<br/>Disease"]
SLC6A4 -->|"complex_role"| Parkinson["Parkinson's<br/>Disease"]
SLC6A4 -->|"complex_role"| ALS["Amyotrophic Lateral<br/>Sclerosis"]
SLC6A4 -->|"associated_with"| MS["Multiple<br/>Sclerosis"]

%% Therapeutic Implications
SLC6A4 -->|"target_for"| SSRI_Therapy["SSRI<br/>Treatment"]
SSRI_Therapy -->|"may_benefit"| Cognitive["Cognitive<br/>Function"]

%% Protective Mechanisms
Synaptic -->|"maintains"| Neural_Health["Neural Network<br/>Integrity"]

%%

Serotonin Transporter (SERT) Protein

Pathway Diagram

Introduction

Slc6A4 Protein is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.

<div class="infobox infobox-protein"> [@coleman2019]
<table> [@kristensen2011]
<tr><th colspan="2" style="background:#f0f0f0; text-align:center;">Serotonin Transporter (SERT)</th></tr>
<tr><td><b>Gene Symbol</b></td><td>[SLC6A4](/genes/slc6a4)</td></tr>
<tr><td><b>UniProt ID</b></td><td>[P31645](https://www.uniprot.org/uniprot/P31645)</td></tr>
<tr><td><b>PDB ID</b></td><td>5I6X, 6DZZ, 6V02</td></tr>
<tr><td><b>Molecular Weight</b></td><td>63 kDa (glycosylated)</td></tr>
<tr><td><b>Subcellular Localization</b></td><td>Plasma membrane, presynaptic terminal</td></tr>
<tr><td><b>Protein Family</b></td><td>SLC6 family (Na+/Cl- dependent neurotransmitter transporters)</td></tr>
<tr>
<td class="label">Associated Diseases</td>
<td><a href="/wiki/als" style="color:#ef9a9a">ALS</a>, <a href="/wiki/alzheimer" style="color:#ef9a9a">ALZHEIMER</a>, <a href="/wiki/alzheimer's" style="color:#ef9a9a">ALZHEIMER'S</a>, <a href="/wiki/alzheimer's-disease" style="color:#ef9a9a">ALZHEIMER'S DISEASE</a>, <a href="/wiki/anxiety" style="color:#ef9a9a">ANXIETY</a></td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">176 edges</a></td>
</tr>
</table>
</div>

Overview

The Serotonin Transporter (SERT) is a membrane protein that reuptakes serotonin (5-HT) from the synaptic cleft back into the presynaptic neuron, terminating serotonin signaling[@rudnick2006]. Encoded by the SLC6A4 gene, SERT is the target of widely used antidepressant medications including selective serotonin reuptake inhibitors (SSRIs). SERT plays critical roles in mood regulation, sleep, appetite, and cognitive function, making it a key protein in both normal neurophysiology and neuropsychiatric disorders.

Structure

Domain Architecture

SERT is a member of the SLC6 family with 12 transmembrane domains:

• N-terminus: Intracellular, contains phosphorylation sites
• Transmembrane domains 1-12: Alpha-helical membrane segments
• Extracellular loops: glycosylation sites, disulfide bonds
• C-terminus: Intracellular, contains PDZ-binding motif

Crystal Structure

Recent cryo-EM structures have revealed the transport mechanism[@coleman2019]:

• Outward-facing conformation: Substrate binding site open to extracellular space
• Inward-facing conformation: Substrate binding site open to cytoplasm
• Leucine transporter (LeuT) homology: Bacterial homolog providing structural insights

Post-Translational Modifications

• N-glycosylation: Asn-glycosylation in extracellular loops
• Phosphorylation: Serine/threonine phosphorylation regulates activity
• Palmitoylation: Membrane anchoring

Normal Function

Transport Mechanism

SERT uses a symport mechanism coupling serotonin transport to Na+ and Cl- gradients[@kristensen2011]:

Substrate Specificity

| Substrate | Affinity | Notes |
|-----------|----------|-------|
| Serotonin (5-HT) | High | Primary substrate |
| Dopamine | Low | Minor substrate |
| Tryptamine | Moderate | Endogenous substrate |
| MDMA | High | Substrate, releaser |

Regulation

• Phosphorylation: PKC activation reduces activity
• Substrate trafficking: Acute regulation via endocytosis
• Transcriptional control: Long-term regulation via gene expression

Expression Pattern

Brain Regional Distribution

SERT is expressed in serotonin-producing [neurons](/entities/neurons):

• Raphe nuclei: Dorsal and median raphe (primary site)
• [Cortex](/brain-regions/cortex): Moderate expression in prefrontal, temporal regions
• [Hippocampus](/brain-regions/hippocampus): Dentate gyrus, CA regions
• Amygdala: Moderate expression
• Basal ganglia: Low expression

Cellular Localization

• Plasma membrane: Primary location on presynaptic terminals
• Synaptic vesicles: Vesicular SERT for reuptake
• Dendrites: Dendritic SERT for autoreceptor function
• Non-neuronal: Platelets, intestinal enterochromaffin cells

Role in Neurodegeneration

Alzheimer's Disease

SERT alterations in AD[^4]:

• Serotonergic deficits: Reduced SERT binding in AD cortex
• Depression comorbidity: High depression in AD patients linked to SERT
• Amyloid interactions: [Aβ](/proteins/amyloid-beta) may affect SERT function
• Therapeutic implications: SSRIs may have disease-modifying effects

Parkinson's Disease

• Depression in PD: SERT polymorphisms affect PD depression risk
• SSRI use: May affect L-DOPA efficacy
• Serotonergic neurons: PD affects raphe nuclei

Psychiatric Disorders

• Major depressive disorder: SSRIs target SERT
• Anxiety disorders: SERT function altered
• Autism: SERT polymorphisms associated
• OCD: SERT as therapeutic target

Therapeutic Targeting

SSRIs (Selective Serotonin Reuptake Inhibitors)

| Drug | Approval | Notes |
|------|----------|-------|
| Fluoxetine (Prozac) | 1987 | First SSRI |
| Sertraline (Zoloft) | 1991 | Highly selective |
| Paroxetine (Paxil) | 1992 | Short half-life |
| Escitalopram (Lexapro) | 2002 | Most selective |
| Citalopram (Celexa) | 1998 | Racemic mixture |

Other SERT-Targeting Drugs

• Serotonin-norepinephrine reuptake inhibitors (SNRIs): Venlafaxine, duloxetine
• Tricyclic antidepressants (TCAs): Imipramine, amitriptyline
• Monoamine oxidase inhibitors (MAOIs): Indirect SERT effects

Side Effects

• Gastrointestinal: Nausea, diarrhea
• Sexual dysfunction: Anorgasmia, decreased libido
• CNS: Insomnia, agitation, headache
• Serotonin syndrome: With combinations

Animal Models

• SERT knockout mice: Anxiety-related behaviors
• Transgenics: Overexpression and mutant models
• Conditional knockouts: Brain-specific deletion

Research Directions

• Structural biology: Cryo-EM structures of human SERT
• Polymorphisms: 5-HTTLPR and disease risk
• Biomarkers: SERT imaging in disease
• Novel therapeutics: Allosteric modulators

Background

The study of Slc6A4 Protein has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.

Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.

See Also

• SLC6A4 Gene
• [Serotonin Signaling](/mechanisms/serotonin-signaling)
• SSRIs
• [Depression](/diseases/depression)
• [Alzheimer's Disease](/diseases/alzheimers-disease)
• [Parkinson's Disease](/diseases/parkinsons-disease)

External Links

• [UniProt P31645](https://www.uniprot.org/uniprot/P31645)
• [PDB: 5I6X](https://www.rcsb.org/structure/5I6X)
• [Human Protein Atlas](https://www.proteinatlas.org/ENSG00000108576-SLC6A4)
• [IUPHAR Database](https://www.guidetopharmacology.org/target/1388)

References